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-The 5-year survival for lung cancer in Canada is 14% in males and 20% in females 2 .
• Approximately, 85% of all lung cancer cases are non-small cell lung cancer (NSCLC) 3 ; about 2% to 7% of patients with NSCLC have rearrangements in anaplastic lymphoma kinase (ALK) gene and are considered as ALK-positive (ALK+) 4, 5 .
• ALK+ NSCLC is more prevalent in patients with adenocarcinomas of younger age, or never-or light smokers 6 , with the majority of patients (70%) diagnosed at an advanced stage 7 .
• Crizotinib has been recommended for funding as first-line therapy, and has most recently been used as second-line therapy 3 .
• Even after initial response, almost all patients treated with crizotinib acquire resistance and progress within first year of treatment 8 , with limited to no treatment options post discontinuation 3 .
• Ceritinib has been approved by Health Canada on March 27, 2015 and has been reviewed by the Canadian HTA agency, the pan-Canadian Oncology Drug Review, with the initial recommendation issued on October 1, 2015.
OBJECTIVE
• To assess the cost-effectiveness of ceritinib vs alternatives, in patients with ALK+ NCLC who have discontinued treatments with crizotinib, from a Canadian perspective.
METHODS

Type of Analysis
• An excel based partitioned survival Markov model was developed to compare ceritinib vs other alternatives in patients with ALK+ NSCLC who were previously treated with an ALK inhibitor.
• The model consists of 3 mutually exclusive health states: stable disease (SD), progressive disease (PD), and death (D) (Figure 1 ). At the start of the treatment, it was assumed that all patients enter the stable disease state. The proportion of patients in the progressive disease state at each cycle was calculated as the difference between the proportion of patients who died and the proportion of patients who would remain in the 'stable disease' state.
• A cycle with an average of 30.44 days was considered to be sufficient to capture the complexities of the disease. 
Population
• The model used data reported from ASCEND-1 (n = 163, NCT01283516) and ASCEND-2 (n = 140, NCT01685060) specifically patients receiving ceritinib after one prior ALK inhibitor. The model assumed that all patients started the treatment at age 53, the median age of patients in the ASCEND-1 trial. Body surface area (BSA) was used to estimate the doses needed for chemotherapy (mean BSA was 1.79/m 2 ). .
• Pemetrexed, best supportive care (BSC), and a separate arm taking into all non-ceritinib treatments reported in Canadian chart study termed as "historical controls" (HC) were considered appropriate as comparators in the base case based on their utilization reported in the retrospective Canadian chart study. Comparison to docetaxel has been assessed as a sensitivity analysis.
• In the absence of a head-to-head randomized trial comparing ceritinib vs any other alternatives, transition probabilities for comparators were obtained from published clinical trials in patients with ALK+ NSCLC, general NSCLC population and from a Canadian retrospective chart study in patients with ALK+ treated with crizotinib.
• Comparators and sources of efficacy inputs are presented in Table 1 .
Parameter Estimation
• Patient-level time-to-event data for PFS and OS were generated from published Kaplan-Meier curves using the digitization software (Engauge digitization software).
• Based on the extracted survival curves, and on the reported numbers of events and patients at risk at various time points, approximate individual patient data were generated using the approach described by Guyot et al 15 . An analysis based on observed Kaplan-Meier was derived based on data available over the trial period.
• Extrapolation beyond the trial period: PFS and OS were estimated for each treatment using parametric models (models included Weibull, exponential, Gompertz, log-logistic and log-normal).
Costs
• Costs in the stable disease included cost of active treatment (includes drug administration and delivery for chemotherapy). Both stable disease and progressive disease included outpatient visits, laboratory and radiologic monitoring).
• The costs for chemotherapy were derived from the dosing schedules reported in the treatment monographs from Cancer Care, Ontario. Unit costs were retrieved from IMSB DeltaPA databases were used to retrieve unit costs for concomitant medication 16 .
• Incidence of AE for ceritinib was obtained from ASCEND-1 and for pemetrexed or docetaxel was obtained from Hanna et al 12 .
Unit costs for AEs were obtained from the Ontario Case Costing initiative.
• Health care costs included in the model are presented in Table 2 . Abbreviations: HC, historical controls; BSC, best supportive care. *Pre-progression costs include, costs of HCP visits, laboratory and radiologic monitoring costs. Pre and post progression costs correspond to the cost of BSC, as no active treatment was included in the cost of BSC.
Utilities
• Health utilities were obtained mainly from 2 studies, multinational, prospective, cross-sectional patient survey study in the real-world setting (Chouaid et al) wherein EQ-5D and EQ-VAS scores were transformed into utility values and a study eliciting UK societal based utility values by Nafees et al. Disutilities were extracted from Nafees et al (Table 3) . 
Key Model Assumptions And Base Case Assumptions
• Health utility for SD state was adjusted based on the response rate for each treatment and were derived from Chouaid and colleagues.
An alternative scenario includes health utility scores derived from previous patients with ALK+ NSCLC treated with crizotinib as reported by Blackhall and colleagues 17 .
• Time horizon in the base case: 4 years, although 10% of the patients were alive in the ceritinib arm.
• Discount rate of 5% were applied in both costs and benefits.
• Parametric functions: Weibull functions for all comparators, except the exponential function was applied in the historical control arm for stable disease state; Weibull functions were applied for all.
• Mean dose intensity was applied for all interventions.
Sensitivity Analyses
• To test the robustness of the model, univariate and probabilistic sensitivity analyses were performed. The probability of ceritinib to be cost-effective compared to comparator treatment was estimated based on different willingness to pay thresholds.
RESULTS
Base Case Deterministic Results
• In the deterministic analysis, treatment with ceritinib is associated with 0.86 QALYs at an incremental cost per QALY of $149,117 comparing ceritinib vs BSC, $80,100 vs pemetrexed, and $104,436 vs HCs ( Table 4) . Alternative Scenarios
• Results of sensitivity analysis with survival based on Kaplan-Meier (KM) curves are presented in Table 5 . One-way Sensitivity Analyses
• All parameters were varied in one-way sensitivity analyses.
• Parameters most sensitive when compared to alternatives were: cost of ceritinib until treatment discontinuation, unit cost of ceritinib and dose intensity, unit cost of pemetrexed, time horizon, and parametric functions (log-normal, log-logistic, Gompertz).
Probabilistic Sensitivity Analysis
• Probabilistic sensitivity analysis (PSA) results predicted ceritinib to be the most cost-effective treatment compared to other alternatives with willingness to pay $150 000 (Figure 2) . 
LIMITATIONS
• Cost-effectiveness of ceritinib was derived based on the single-arm study, and the comparators data was drawn from multiple previously published studies.
• Data source was not entirely representative of ceritinib population (secondline and third-line) except BSC arm and pemetrexed data pertained to the population that had 1 prior line of chemotherapy.
• Costs associated with the BSC arm could be underestimated, since all reports were reported in the retrospective Canadian chart.
• The costs of post-progression in the pemetrexed arm may be underestimated, as it was reported that nearly 40% of patients discontinuing treatment on pemetrexed received further anti-neoplastic treatment.
• Due to the limitation in the sample size for the historical arm, the analysis included patients who received systemic treatment and no further treatment. As such, the time of systemic treatment could be overestimated as it was estimated from the time of discontinuation with crizotinib, rather than from the time of treatment initiation.
CONCLUSION
• Results of the base case analysis suggest that ceritinib is costeffective for the treatment of patients with ALK+ NSCLC, assuming a threshold for oncology treatments of $150 000 CAN in Canada.
• The results are further supported by one-way sensitivity analysis and PSA.
• In light of unsatisfactory treatment alternatives and poor survival in patients discontinuing treatment with crizotinib, ceritinib appears to be cost-effective compared to other available treatments in patients with ALK+ NSCLC.
